Scleroderma Foundation's 13th Annual National Patient Education Conference Is Here PDF Print E-mail
Wednesday, 06 July 2011 10:31
Nearly 600 people are anticipated to visit the heart of San Francisco Friday, July 8, through Sunday, July 10, for the Scleroderma Foundation's 13th Annual National Patient Education Conference. Patients, family members, caregivers, doctors and other health care professionals representing 40 states, the District of Columbia, Canada and Mexico will converge at the Hilton San Francisco Union Square for this engaging and educational event that focuses on scleroderma, a rare autoimmune disease.

This year's conference features a variety of workshops hosted by leading scleroderma researchers and medical professionals. Andreas Baxevanis, Ph.D., will give the opening keynote address on the promise of genomics and genome-based personal health care in disease management. James Lemons, Ed.D., will present the closing keynote on "Pain – The Psychology and Physiology: There is Hope." Dr. Baxevanis is Assistant Director for Computational Bioscience, Office of Intramural Research at the National Institutes of Health (NIH), and Associate Investigator, Division of Intramural Research at the National Human Genome Research Institute in Bethesda, Md. Dr. Lemons is the director of The Lemons Center for Behavioral Pain Management in Lenexa, Kan., and a medical psychologist.

Other conference highlights include:
  • Fifty-six workshops and panel discussions for patients, family members and caregivers.
  • Special sessions for children with scleroderma and their families.
  • Representatives from the University of Texas Scleroderma Family Registry and DNA Repository and the University of Texas Southwestern Morphea Registry and DNA Repository will be at the conference seeking interested individuals to serve as donors and controls for scleroderma research.
  • Annual Awards Banquet to honor Scleroderma Foundation members, volunteers and chapters of the Foundation for their dedication and work to advance the mission of the Scleroderma Foundation, and bring awareness to the issues facing the scleroderma patient community.

For more information about scleroderma and the National Patient Education Conference, visit www.scleroderma.org.

 
More articles :

» Enhanced Survival Found With Early Detection of Scleroderma-Associated PAH

Early detection of incident systemic sclerosis–associated enhanced survival in a prospective cohort study of 131 patients from the multicenter PHAROS, according to data presented at the annual meeting of the American College of Rheumatology.The...

» Restoring Alkalinity in the Body

All foods are "burned" within the body, leaving an ash as the result of the "burning" or digestion. This food ash can be neutral, acid or alkaline, depending largely on the mineral composition of the foods.Some foods leave an acid residue or ash,...

» Cancer Drug May Also Work for Scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or Scleroderma.The drug, with the generic name bortezomib, stopped the production of fibrotic proteins in...

» Sildenafil Reduces Raynaud's Frequency in Systemic Sclerosis Patients

Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of in patients with limited cutaneous systemic sclerosis (lcSSc), also known as . The double-blind, placebo-controlled...

» Pressure and Pain In Systemic Sclerosis/ Scleroderma

Begonya Alcacer-Pitarch, Maya H Buch, Janine Gray, Christopher P Denton, Ariane Herrick, Nuria Navarro-Coy, Howard Collier, Lorraine Loughrey, Sue Pavitt, Heidi J Siddle, Jonathan Wright, Philip S Helliwell, Paul Emery, Anthony C RedmondStudy...

» Potential Therapy for Scleroderma Lung Disease Uncovered

Investigators, partially supported by the , have found that a deficiency in the protein caveolin-1 (cav-1) is linked to the development of, the scarring of lung tissue that causes disability and death in people with . The scientists, from the...